TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25529851

Group type: EXPERIMENTAL
Intervention: Intramuscular dexmedetomidine (1 µg·kg‐1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Midazolam (0.02 mg·kg‐1)
Number of subjects: 40
Study: 22986757

Group type: EXPERIMENTAL
Intervention: Let's Read program delivered at 4, 12, 18, and 42 months during universal well-child care visits
Number of subjects: 630
Study: 19571157

Group type: EXPERIMENTAL
Intervention: Modified wheat flakes (MWF)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard wheat flakes (SWF)
Number of subjects: 11

Group type: COMPARATOR
Intervention: White-wheat bread (WWB)
Number of subjects: 11
Study: 17353101

Group type: EXPERIMENTAL
Intervention: Bupropion SR (150 mg twice daily)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 225
Study: 15084616

Group type: EXPERIMENTAL
Intervention: Gemcitabine + Tipifarnib (200 mg bid orally continuously; gemcitabine at 1,000 mg/m² intravenously weekly x 7 for 8 weeks, then weekly x 3 every 4 weeks)
Number of subjects: 688

Group type: COMPARATOR
Intervention: Gemcitabine + Placebo (gemcitabine at 1,000 mg/m² intravenously weekly x 7 for 8 weeks, then weekly x 3 every 4 weeks)
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Gemcitabine + Tipifarnib
Number of subjects: 688

Group type: COMPARATOR
Intervention: Gemcitabine + Placebo
Number of subjects: 688
Study: 11347792

Group type: EXPERIMENTAL
Intervention: Discussion of urinary incontinence (UI) with primary care provider
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Perceptions of urinary incontinence as a problem
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Perceptions of urinary incontinence as a normal part of aging
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Barriers to discussing urinary incontinence
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Frequency of urinary incontinence episodes
Number of subjects: 49
Study: 9684793

Group type: EXPERIMENTAL
Intervention: INR values obtained using 8 different thromboplastin reagents in patients without LA (n = 47)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: INR values obtained using 8 different thromboplastin reagents in patients with LA (n = 43)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: INR values obtained with recombinant thromboplastin Innovin in patients with LA
Number of subjects: 90
Study: 8053507

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty alone (n = 23)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Supplemental atherectomy
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: ABI increase by 0.3 or more
Number of subjects: 57

Group type: COMPARATOR
Intervention: ABI increase less than or equal to 0.1
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Short occlusions (less than or equal to 5 cm, n = 8)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Long occlusions (greater than 25 cm, n = 16)
Number of subjects: 57
Study: 2722598

Group type: EXPERIMENTAL
Intervention: Fluosol-DA 20% infusion (8 mL/Kg, 6 infusions) + 100% oxygen breathing
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Fluosol-DA 20% infusion (various dosages and infusions) + 100% oxygen breathing
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Fluosol-DA 20% infusion
Number of subjects: 46
Study: 30594631

Group type: COMPARATOR
Intervention: Control (EX0) - ExciTE F adhesive
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: EX2 - 2 wt% proanthocyanidins added to ExciTE F
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: EX5 - 5 wt% proanthocyanidins added to ExciTE F
Number of subjects: 45
Study: 28595464

Group type: EXPERIMENTAL
Intervention: Baroreflex activation therapy (BAT) for 16 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Continuous pharmacotherapy (BAT off) for 8 months followed by BAT for 8 months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: BAT for 3 months after 16 months
Number of subjects: 100
Study: 25281894

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (3 mg Bid)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Systemic methylprednisolone (40 mg Qd for three days, then 8 mg Bid)
Number of subjects: 30
Study: 23698078

Group type: EXPERIMENTAL
Intervention: Training Group (TG) - 2-week landing training, 3 times per week, 6 sessions
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control Group (CG) - no intervention
Number of subjects: 20
Study: 21442135

Group type: EXPERIMENTAL
Intervention: Weekly 1‐hr training session including aerobic interval training, circuit training, and whole body vibration
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 8
Study: 18639327

Group type: EXPERIMENTAL
Intervention: Tolterodine ER (4 mg once daily)
Number of subjects: 850

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 850
Study: 17469502

Group type: EXPERIMENTAL
Intervention: Elmex toothpaste (amine fluoride, 0.125% F) without rinsing
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Meridol toothpaste (amine fluoride, stannous(II) fluoride, 0.14% F) without rinsing
Number of subjects: 120

Group type: COMPARATOR
Intervention: Both toothpastes with rinsing
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both toothpastes without rinsing
Number of subjects: 120
Study: 12601286

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 298

Group type: COMPARATOR
Intervention: PTCA and CABG combined
Number of subjects: 298
Study: 10999783

Group type: EXPERIMENTAL
Intervention: Low isoflavone diet (1.00 mg/kg body wt/day, averaging 65 mg/day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: High isoflavone diet (2.01 mg/kg body wt/day, averaging 130 mg/day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Low and high isoflavone diets
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control diet (0.13 mg/kg body wt/day, averaging 8 mg/day)
Number of subjects: 31
Study: 8852910

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b alone (10 million units/m2, three times weekly for 1 year)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b after prednisone priming (10 million units/m2, three times weekly for 1 year)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no treatment, n=9)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Treated patients (combined interferon groups)
Number of subjects: 31
Study: 1479270

Group type: EXPERIMENTAL
Intervention: Freshening the edge of the defect and placing a small piece of 0.13 mm silastic sheeting over the defect
Number of subjects: 152

Group type: COMPARATOR
Intervention: Freshening the edge of the defect only
Number of subjects: 152
Study: 6543431

Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cefamandole
Number of subjects: 30
Study: 29479727

Group type: EXPERIMENTAL
Intervention: Potassium hydroxide 10%
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Potassium hydroxide 15%
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 26885526

Group type: EXPERIMENTAL
Intervention: HIT (High Intensity Training)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: HIT&P (High Intensity Training with Protein Supplementation)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: HVHIT (High Volume/High Intensity Training)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 120
Study: 25626751

Group type: EXPERIMENTAL
Intervention: Whole-task OSCE stations (hypothesis-driven physical examination)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Part-task OSCE stations (examination of a healthy patient)
Number of subjects: 40
Study: 23758485

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate once-daily (QD; 900 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate twice-daily (BID; 450 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oxcarbazepine BID (450 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate QD, ESL BID, and OXC BID
Number of subjects: 12
Study: 19897177

Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray (18 or 24 IU)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 18199894

Group type: EXPERIMENTAL
Intervention: TZP-101 (20-600 microg/kg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 16775677

Group type: EXPERIMENTAL
Intervention: Three-dimensional ultrasound (11.7 MHz linear transducer)
Number of subjects: 34

Group type: COMPARATOR
Intervention: MRI
Number of subjects: 34
Study: 14967872

Group type: EXPERIMENTAL
Intervention: Carbohydrate meal (C; 3 g carbohydrate/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isoenergetic fat meal (F; 1.3 g fat/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Placebo meal (P; no energy content)
Number of subjects: 8
Study: 10840251

Group type: EXPERIMENTAL
Intervention: Information cards (intervention group)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Non-intervention (control group)
Number of subjects: 76
Study: 9085972

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine with propofol
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Topical nitroglycerin ointment with plain propofol
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Topical nitroglycerin ointment with propofol mixed with lidocaine
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo with plain propofol
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Propofol mixed with lidocaine
Number of subjects: 124
Study: 8458683

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg, product A)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Omeprazole (20 mg, product B)
Number of subjects: 8
Study: 3094054

Group type: EXPERIMENTAL
Intervention: Marijuana smoking
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo cigarette smoking
Number of subjects: 10
Study: 31030229

Group type: EXPERIMENTAL
Intervention: 365 μm holmium laser
Number of subjects: 200

Group type: COMPARATOR
Intervention: 200 μm holmium laser (Control)
Number of subjects: 200
Study: 30439316

Group type: EXPERIMENTAL
Intervention: Progressive early bed physical activity (15-30 minutes, twice a day)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Intermittent pneumatic compression (IPC) (30 minutes, twice a day)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Progressive early bed physical activity
Number of subjects: 160

Group type: COMPARATOR
Intervention: Intermittent pneumatic compression (IPC)
Number of subjects: 160
Study: 27857211

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Moxibustion
Number of subjects: 36
Study: 24595965

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 23539698

Group type: EXPERIMENTAL
Intervention: Medial-opening extension gap
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Lateral-opening extension gap
Number of subjects: 277

Group type: COMPARATOR
Intervention: No asymmetric gap
Number of subjects: 277
Study: 20512409

Group type: EXPERIMENTAL
Intervention: Family intervention (SET)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Group intervention
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 126
Study: 18345549

Group type: COMPARATOR
Intervention: Subcutaneous injection of physiological saline (placebo)
Number of subjects: 29
Study: 16943455

Group type: EXPERIMENTAL
Intervention: Vitamin E (50 mg/day)
Number of subjects: 14573

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14573
Study: 14689793

Group type: EXPERIMENTAL
Intervention: Mairin-P (isoniazid 60 mg, rifampicin 120 mg, pyrazinamide 300 mg, ethambutol hydrochloride 225 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mairin-P
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment regimens with antituberculous drugs
Number of subjects: 0
Study: 11205722

Group type: EXPERIMENTAL
Intervention: Management strategies for advanced CHF
Number of subjects: 0
Study: 8880740

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% and ketamine 0.3%
Number of subjects: 18

Group type: COMPARATOR
Intervention: Bupivacaine 0.5% only
Number of subjects: 18
Study: 1390487

Group type: EXPERIMENTAL
Intervention: PhXA34 0.3 micrograms
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PhXA34 1 microgram
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PhXA34 3 micrograms
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PhXA34 10 micrograms
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 40
Study: 3100871

Group type: EXPERIMENTAL
Intervention: Flutamide + orchiectomy
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Flutamide + LHRH agonist [D‐Trp6]LHRH ethylamide
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Flutamide alone for previously castrated patients
Number of subjects: 334

Group type: COMPARATOR
Intervention: Combination therapy (Flutamide + LHRH agonist)
Number of subjects: 334
Study: 31167902

Group type: EXPERIMENTAL
Intervention: Menthol cigarette ban
Number of subjects: 1197

Group type: EXPERIMENTAL
Intervention: All menthol product ban
Number of subjects: 1197

Group type: EXPERIMENTAL
Intervention: Green replacement
Number of subjects: 1197

Group type: COMPARATOR
Intervention: No ban
Number of subjects: 1197
Study: 30088473

Group type: EXPERIMENTAL
Intervention: Interceptor® G2 (unwashed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interceptor® G2 (washed 20 times)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interceptor® LN (unwashed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interceptor® LN (washed 20 times)
Number of subjects: 0
Study: 27936214

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block (post‐tetanic‐count 2‐3)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Moderate neuromuscular block (train-of-four 1-2)
Number of subjects: 100
Study: 25338443

Group type: EXPERIMENTAL
Intervention: Comprehensive treatment group
Number of subjects: 300

Group type: COMPARATOR
Intervention: Conventional treatment group
Number of subjects: 300
Study: 22071882

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg and 1.25 mg
Number of subjects: 39
Study: 23050889

Group type: EXPERIMENTAL
Intervention: Structured psychoeducation programme
Number of subjects: 109
Study: 18523833

Group type: EXPERIMENTAL
Intervention: Posterior-stabilized mobile-bearing TKA
Number of subjects: 103

Group type: COMPARATOR
Intervention: Posterior-stabilized fixed-bearing TKA
Number of subjects: 103
Study: 19193602

Group type: EXPERIMENTAL
Intervention: Need to belong (experimental intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community acceptance (experimental intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control variables (Study 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Causal effect of need to belong (Study 2)
Number of subjects: 0
Study: 15896421

Group type: EXPERIMENTAL
Intervention: Enteral solution of arginine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control solution of amino-acids
Number of subjects: 8
Study: 11447774

Group type: EXPERIMENTAL
Intervention: Occlusive calcipotriol 50 micrograms/mg ointment applied twice-weekly overnight under occlusion
Number of subjects: 39

Group type: COMPARATOR
Intervention: Nonocclusive calcipotriol 50 micrograms/mg ointment applied twice-daily
Number of subjects: 39
Study: 9746766

Group type: EXPERIMENTAL
Intervention: Low-dose 6-methylprednisolone (6MPred; 2 mg/kg/d; n = 47)
Number of subjects: 95

Group type: COMPARATOR
Intervention: High-dose 6-methylprednisolone (6MPred; 10 mg/kg/d; n = 48)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Low-dose 6-methylprednisolone (6MPred; 2 mg/kg/d; switched to high-dose after 5 days)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Low-dose 6-methylprednisolone (6MPred; 2 mg/kg/d; continued with tapering doses)
Number of subjects: 95
Study: 7846423

Group type: EXPERIMENTAL
Intervention: medroxy-progesterone acetate (MPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: alpha-interferon (alpha-IFN)
Number of subjects: 0
Study: 3167248

Group type: EXPERIMENTAL
Intervention: Conjoint Therapy (8 sessions)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Advice Counselling (1 session)
Number of subjects: 116
Study: 30759089

Group type: EXPERIMENTAL
Intervention: nVNS
Number of subjects: 30
Study: 30139465

Group type: EXPERIMENTAL
Intervention: Oxygen supplementation
Number of subjects: 622

Group type: COMPARATOR
Intervention: Ambient air
Number of subjects: 622
Study: 26936519

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 356

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study: 24850059

Group type: EXPERIMENTAL
Intervention: Free vaccination in the FATC (Group B)
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Both interventions (Group C)
Number of subjects: 872

Group type: COMPARATOR
Intervention: Training on HBV epidemiology, risk factors and vaccination (Group A)
Number of subjects: 872
Study: 22144699

Group type: EXPERIMENTAL
Intervention: IVMP+IVIG
Number of subjects: 122

Group type: COMPARATOR
Intervention: IVIG
Number of subjects: 122
Study: 18849028

Group type: EXPERIMENTAL
Intervention: L-arginine (20 mg/min) and tetrahydrobiopterin (BH(4)) (500 microg/min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: L-arginine and BH(4) infusion
Number of subjects: 12
Study: 17493109

Group type: EXPERIMENTAL
Intervention: Industry-supported trials (31 of 49, 63%)
Number of subjects: 18238

Group type: EXPERIMENTAL
Intervention: Industry-supported trials
Number of subjects: 18238

Group type: COMPARATOR
Intervention: Non-industry trials
Number of subjects: 18238

Group type: EXPERIMENTAL
Intervention: Overall NRT trials
Number of subjects: 18238

Group type: EXPERIMENTAL
Intervention: Industry trials after imputation adjustment
Number of subjects: 18238
Study: 16202894

Group type: EXPERIMENTAL
Intervention: Heparin-bonded cardiopulmonary bypass circuits (HBCPB)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Nonheparin-coated cardiopulmonary bypass circuits and EACA (EACPB)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Nonheparin-coated bypass circuits and placebo (control)
Number of subjects: 71
Study: 12376201

Group type: EXPERIMENTAL
Intervention: Anastrozole alone or in combination with tamoxifen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 0
Study: 10411413

Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg/day with an oral contraceptive
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate 50 mg/day on days 1 to 10 with an oral contraceptive
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Flutamide 250 mg twice a day
Number of subjects: 81
Study: 8866899

Group type: EXPERIMENTAL
Intervention: Clinic blood pressure measurements (average of three measurements, sphygmomanometry)
Number of subjects: 1438

Group type: EXPERIMENTAL
Intervention: Home blood pressure measurements (average of morning and evening measurements, semiautomatic device)
Number of subjects: 1438

Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure measurements (automatic readings at 20 min intervals, Spacelabs 90207)
Number of subjects: 1438

Group type: EXPERIMENTAL
Intervention: Daytime average blood pressure
Number of subjects: 1438

Group type: EXPERIMENTAL
Intervention: Night-time blood pressure
Number of subjects: 1438

Group type: EXPERIMENTAL
Intervention: Upper limit of normality for home blood pressure
Number of subjects: 1438

Group type: EXPERIMENTAL
Intervention: Upper limit of normality for ambulatory blood pressure
Number of subjects: 1438
Study: 2185691

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (750 mg every 12 h)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (750 mg every 12 h) and oral rifampin (300 mg every 12 h)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ciprofloxacin and rifampin (group B) compared to historical controls
Number of subjects: 12
Study: 84900

Group type: EXPERIMENTAL
Intervention: 3% acycloguanosine eye ointment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Topical acycloguanosine alone
Number of subjects: 24
Study: 31120518

Group type: EXPERIMENTAL
Intervention: Testosterone plus placebo
Number of subjects: 102

Group type: COMPARATOR
Intervention: Dutasteride
Number of subjects: 102
Study: 27859252

Group type: EXPERIMENTAL
Intervention: Bacillus subtilis-, Bacillus megaterium-, and Bacillus pumulus-containing toothpaste, mouthrinse and toothbrush cleaner for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo toothpaste, mouthrinse and toothbrush cleaner for 8 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bacillus subtilis-, Bacillus megaterium-, and Bacillus pumulus-containing products
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo products
Number of subjects: 40
Study: 26345602

Group type: EXPERIMENTAL
Intervention: ALA (600 mg qd)
Number of subjects: 45

Group type: COMPARATOR
Intervention: ALA withdrawal
Number of subjects: 45
Study: 23422292

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 21250901

Group type: EXPERIMENTAL
Intervention: MVM+D (multivitamin and mineral supplement plus vitamin D 1,200 IU/day)
Number of subjects: 61

Group type: COMPARATOR
Intervention: MVM (multivitamin and mineral supplement)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Vitamin D 1,200 IU/day
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 61
Study: 19625236

Group type: EXPERIMENTAL
Intervention: Orally administered antidiabetic drugs (OADs) combination therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-tablet OAD combinations
Number of subjects: 0
Study: 18177193

Group type: EXPERIMENTAL
Intervention: Revision surgery
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nonrevision (no surgery)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Noncleft control
Number of subjects: 100
Study: 15057587

Group type: EXPERIMENTAL
Intervention: Submucosal hemorrhoidectomy with radiofrequency bistoury
Number of subjects: 102

Group type: COMPARATOR
Intervention: Conventional Parks' operation
Number of subjects: 102